Annika Werly, Mareike Hampel, Thomas Hielscher, Kosima Zuern, Sophia K. Schmidt, Alissa Visram, Marc S. Raab, Carsten Mueller-Tidow, Hartmut Goldschmidt, Elias K. Mai
{"title":"Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma","authors":"Annika Werly, Mareike Hampel, Thomas Hielscher, Kosima Zuern, Sophia K. Schmidt, Alissa Visram, Marc S. Raab, Carsten Mueller-Tidow, Hartmut Goldschmidt, Elias K. Mai","doi":"10.1038/s41408-024-01159-8","DOIUrl":"https://doi.org/10.1038/s41408-024-01159-8","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"43 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142431362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Susanne Ghandili, Judith Dierlamm, Carsten Bokemeyer, Henrik Kusche, Frederik Peters
{"title":"A German perspective on the impact of socioeconomic status in diffuse large B-cell lymphoma","authors":"Susanne Ghandili, Judith Dierlamm, Carsten Bokemeyer, Henrik Kusche, Frederik Peters","doi":"10.1038/s41408-024-01158-9","DOIUrl":"https://doi.org/10.1038/s41408-024-01158-9","url":null,"abstract":"<p>The prognostic influence of socioeconomic status (SES) on the survival of diffuse large B-cell lymphoma (DLBCL) patients remains controversial. This observational study examines the potential impact of regional SES inequalities on overall survival (OS) among DLBCL patients in Germany. We analyzed data from the German nationwide population-based dataset spanning 2004-2019 sourced from the German Center for Cancer Registry Data (<i>n</i> = 49,465). The primary objective was to assess the 5-year OS among patients with low SES compared to those living in middle and high SES areas. SES was grouped according to quintiles of the German Index of Socioeconomic Deprivation, which summarized nine indicators covering aspects of regional education, employment, and income. DLBCL patients in low SES areas had significantly impaired 5-year OS compared to those in middle and high SES regions (59.2% vs. 61.8% vs. 64.1%, <i>p</i> < 0.0001). Yet, additionally accounting for regional premature mortality removed the impact of SES on survival (Hazard Ratio 0.94, 95% CI 0.87–1.01). Our findings indicate that the prognostic impact of socioeconomic deprivation on long-term survival is not due to variations in diagnosis and treatment of DLBCL itself but rather a higher comorbidity burden.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"26 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142405259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Surbhi Sidana, Andriyana K. Bankova, Hitomi Hosoya, Shaji K. Kumar, Tyson H. Holmes, John Tamaresis, Anne Le, Lori S. Muffly, Sofia Maysel-Auslender, Laura Johnston, Sally Arai, Robert Lowsky, Everett Meyer, Andrew Rezvani, Wen-Kai Weng, Matthew J. Frank, Parveen Shiraz, Holden T. Maecker, Ying Lu, David B. Miklos, Judith A. Shizuru
{"title":"Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma","authors":"Surbhi Sidana, Andriyana K. Bankova, Hitomi Hosoya, Shaji K. Kumar, Tyson H. Holmes, John Tamaresis, Anne Le, Lori S. Muffly, Sofia Maysel-Auslender, Laura Johnston, Sally Arai, Robert Lowsky, Everett Meyer, Andrew Rezvani, Wen-Kai Weng, Matthew J. Frank, Parveen Shiraz, Holden T. Maecker, Ying Lu, David B. Miklos, Judith A. Shizuru","doi":"10.1038/s41408-024-01152-1","DOIUrl":"https://doi.org/10.1038/s41408-024-01152-1","url":null,"abstract":"<p>MGTA-145 or GROβT, a CXCR2 agonist, has shown promising activity for hematopoietic stem cell (HSC) mobilization with plerixafor in pre-clinical studies and healthy volunteers. Twenty-five patients with multiple myeloma enrolled in a phase 2 trial evaluating MGTA-145 and plerixafor for HSC mobilization (NCT04552743). Plerixafor was given subcutaneously followed 2 h later by MGTA-145 (0.03 mg/kg) intravenously with same day apheresis. Mobilization/apheresis could be repeated for a second day in patients who collected <6 ×10<sup>6</sup> CD34+ cells/kg. Lenalidomide and anti-CD38 antibody were part of induction therapy in 92% (<i>n</i> = 23) and 24% (<i>n</i> = 6) of patients, respectively. Median total HSC cell yield (CD34+ cells/kg × 10<sup>6</sup>) was 5.0 (range: 1.1–16.2) and day 1 yield was 3.4 (range: 0.3–16.2). 88% (<i>n</i> = 22) of patients met the primary endpoint of collecting 2 ×10<sup>6</sup> CD34+ cells/kg in ≤ two days, 68% (<i>n</i> = 17) in one day. Secondary endpoints of collecting 4 and 6 × 10<sup>6</sup> CD34+ cells/kg in ≤ two days were met in 68% (<i>n</i> = 17) and 40% (<i>n</i> = 10) patients. Grade 1 or 2 adverse events (AE) were seen in 60% of patients, the most common AE being grade 1 pain, usually self-limited. All 19 patients who underwent transplant with MGTA-145 and plerixafor mobilized HSCs engrafted successfully, with durable engraftment at day 100. 74% (17 of 23) of grafts with this regimen were minimal residual disease negative by next generation flow cytometry. Graft composition for HSCs and immune cells were similar to a contemporaneous cohort mobilized with G-CSF and plerixafor.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"206 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142385536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Melissa A. Hopper, Abigail R. Dropik, Janek S. Walker, Joseph P. Novak, Miranda S. Laverty, Michelle K. Manske, Xiaosheng Wu, Kerstin Wenzl, Jordan E. Krull, Vivekananda Sarangi, Matthew J. Maurer, Zhi-Zhang Yang, Miles D. Del Busso, Thomas M. Habermann, Brian K. Link, Lisa M. Rimsza, Thomas E. Witzig, Stephen M. Ansell, James R. Cerhan, Dragan Jevremovic, Anne J. Novak
{"title":"DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas","authors":"Melissa A. Hopper, Abigail R. Dropik, Janek S. Walker, Joseph P. Novak, Miranda S. Laverty, Michelle K. Manske, Xiaosheng Wu, Kerstin Wenzl, Jordan E. Krull, Vivekananda Sarangi, Matthew J. Maurer, Zhi-Zhang Yang, Miles D. Del Busso, Thomas M. Habermann, Brian K. Link, Lisa M. Rimsza, Thomas E. Witzig, Stephen M. Ansell, James R. Cerhan, Dragan Jevremovic, Anne J. Novak","doi":"10.1038/s41408-024-01145-0","DOIUrl":"https://doi.org/10.1038/s41408-024-01145-0","url":null,"abstract":"<p>This study sheds light on the pivotal role of the oncoprotein DEK in B-cell lymphoma. We reveal <i>DEK</i> expression correlates with increased tumor proliferation and inferior overall survival in cases diagnosed with low-grade B-cell lymphoma (LGBCL). We also found significant correlation between <i>DEK</i> expression and copy number alterations in LGBCL tumors, highlighting a novel mechanism of LGBCL pathogenesis that warrants additional exploration. To interrogate the mechanistic role of DEK in B-cell lymphoma, we generated a DEK knockout cell line model, which demonstrated DEK depletion caused reduced proliferation and altered expression of key cell cycle and apoptosis-related proteins, including Bcl-2, Bcl-xL, and p53. Notably, DEK depleted cells showed increased sensitivity to apoptosis-inducing agents, including venetoclax and staurosporine, which underscores the therapeutic potential of targeting DEK in B-cell lymphomas. Overall, our study contributes to a better understanding of DEK’s role as an oncoprotein in B-cell lymphomas, highlighting its potential as both a promising therapeutic target and a novel biomarker for aggressive LGBCL. Further research elucidating the molecular mechanisms underlying DEK-mediated tumorigenesis could pave the way for improved treatment strategies and better clinical outcomes for patients with B-cell lymphoma.</p><figure></figure>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"64 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142385537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sara Mato, Natalia Castrejón-de-Anta, Ariadna Colmenero, Lorenzo Carità, Julia Salmerón-Villalobos, Joan Enric Ramis-Zaldivar, Ferran Nadeu, Noelia Garcia, Luojun Wang, Jaime Verdú-Amorós, Mara Andrés, Nuria Conde, Verónica Celis, Maria José Ortega, Ana Galera, Itziar Astigarraga, Vanesa Perez-Alonso, Eduardo Quiroga, Aixiang Jiang, David W. Scott, Elias Campo, Olga Balagué, Itziar Salaverria
{"title":"MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma","authors":"Sara Mato, Natalia Castrejón-de-Anta, Ariadna Colmenero, Lorenzo Carità, Julia Salmerón-Villalobos, Joan Enric Ramis-Zaldivar, Ferran Nadeu, Noelia Garcia, Luojun Wang, Jaime Verdú-Amorós, Mara Andrés, Nuria Conde, Verónica Celis, Maria José Ortega, Ana Galera, Itziar Astigarraga, Vanesa Perez-Alonso, Eduardo Quiroga, Aixiang Jiang, David W. Scott, Elias Campo, Olga Balagué, Itziar Salaverria","doi":"10.1038/s41408-024-01153-0","DOIUrl":"https://doi.org/10.1038/s41408-024-01153-0","url":null,"abstract":"<p>Aggressive B-cell non-Hodgkin lymphomas (NHL) in children, adolescents, and young adults (CAYA) include Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and a subset of high-grade tumors with features intermediate between these entities whose genetic and molecular profiles have not been completely elucidated. In this study, we have characterized 37 aggressive B-NHL in CAYA, 33 with high-grade morphology, and 4 DLBCL with <i>MYC</i> rearrangement (<i>MYC</i>-R), using targeted next-generation sequencing and the aggressive lymphoma gene expression germinal center B-cell-like (GCB), activated B-cell-like (ABC), and dark zone signatures (DZsig). Twenty-two tumors had <i>MYC</i>-R without <i>BCL2</i> breaks, and two <i>MYC</i>-non-R cases had <i>BCL6</i> translocations. <i>MYC</i>-R cases, including DLBCL, carried BL-related mutations and copy number alterations. Conversely, <i>MYC</i>-non-R lymphomas had alterations in the B-cell receptor signaling/NF-κB pathway (71%). DZsig was expressed in 12/13 of <i>MYC</i>-R tumors but only in 2/10 of <i>MYC</i>-non-R GCB tumors (<i>P</i> < 0.001). The 3-year event-free survival (EFS) of the whole cohort was 79.6%. <i>TP53</i> and <i>KMT2C</i> mutations conferred inferior outcome (3-year EFS <i>P</i> < 0.05). Overall, <i>MYC</i>-R lymphomas in CAYA have a molecular profile similar to BL regardless of their high-grade or DLBCL morphology, whereas <i>MYC</i>-non-R has more heterogeneous genetic alterations closer to that of DLBCL.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"1 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142383773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benjamin A. Derman, Ajay Major, Jennifer Cooperrider, Ken Jiang, Aubrianna Ramsland, Theodore Karrison, Tadeusz Kubicki, Andrzej J. Jakubowiak
{"title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","authors":"Benjamin A. Derman, Ajay Major, Jennifer Cooperrider, Ken Jiang, Aubrianna Ramsland, Theodore Karrison, Tadeusz Kubicki, Andrzej J. Jakubowiak","doi":"10.1038/s41408-024-01156-x","DOIUrl":"https://doi.org/10.1038/s41408-024-01156-x","url":null,"abstract":"<p>MRD2STOP is a pragmatic trial evaluating maintenance therapy cessation guided by measurable residual disease (MRD) negativity in multiple myeloma (MM). Eligible patients had previous MRD < 10<sup>−5</sup>, received ≥1 year of maintenance, and were prospectively confirmed to have undetectable disease by positron emission tomography, bone marrow (BM) flow cytometry (limit of detection [LoD] 10<sup>−</sup><sup>5</sup>), and BM clonoSEQ (LoD 10<sup>−</sup><sup>6</sup>). BM aspirates enriched for CD138<sup>+</sup> cells were analyzed by clonoSEQ to achieve MRD 10<sup>−</sup><sup>7</sup> sensitivity. We evaluated the incidence of disease resurgence and progression-free survival (PFS), stratified by 10<sup>−</sup><sup>7</sup> status. Forty-seven patients discontinued maintenance after a median of 36 months. Baseline MRD ≥ 10<sup>−</sup><sup>7</sup> was observed in 19% (9/47). The median follow-up post-discontinuation was 30 months. Disease resurgence (MRD 10 ≥ <sup>−</sup><sup>6</sup>) occurred in 11 patients, including 5 disease progressions. One patient died from a second cancer. The estimated 3-year cumulative incidence of disease resurgence was 20% for patients with baseline MRD < 10<sup>−</sup><sup>7</sup> compared to 75% for MRD ≥ 10<sup>−</sup><sup>7</sup> (HR 7.8, 95% CI 2.2-27.6, p = 0.001). Baseline MRD ≥ 10<sup>−</sup><sup>7</sup> was associated with inferior PFS compared to MRD < 10<sup>−</sup><sup>7</sup> (HR 10.1, 95% CI 1.6–62.3; 3-year PFS 49% vs 92%). Maintenance discontinuation in patients with MM and MRD < 10<sup>−</sup><sup>6</sup> led to low rates of disease resurgence. MRD < 10<sup>−</sup><sup>7</sup> may be a superior cessation threshold, requiring further validation.</p><figure></figure>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"12 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142383774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marie Hairing Enemark, Jonas Klejs Hemmingsen, Maja Dam Andersen, Trine Engelbrecht Hybel, Mads Emil Bjørn, Pär Lars Josefsson, Lars Møller Pedersen, Maja Bech Juul, Robert Schou Pedersen, Michael Thorsgaard, Ida Blok Sillesen, Trine Lindhardt Plesner, Stephen Jacques Hamilton-Dutoit, Paw Jensen, Charlotte Madsen, Maja Ludvigsen
{"title":"Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort","authors":"Marie Hairing Enemark, Jonas Klejs Hemmingsen, Maja Dam Andersen, Trine Engelbrecht Hybel, Mads Emil Bjørn, Pär Lars Josefsson, Lars Møller Pedersen, Maja Bech Juul, Robert Schou Pedersen, Michael Thorsgaard, Ida Blok Sillesen, Trine Lindhardt Plesner, Stephen Jacques Hamilton-Dutoit, Paw Jensen, Charlotte Madsen, Maja Ludvigsen","doi":"10.1038/s41408-024-01150-3","DOIUrl":"https://doi.org/10.1038/s41408-024-01150-3","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"8 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142330316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ece Özoğul, Anna Montaner, Melina Pol, Gerard Frigola, Olga Balagué, Charlotte Syrykh, Pablo Bousquets-Muñoz, Romina Royo, Juliette Fontaine, Alexandra Traverse-Glehen, Marco M Bühler, Luca Giudici, Marco Roncador, Thorsten Zenz, Sylvain Carras, Severine Valmary-Degano, Laurence de Leval, Jan Bosch-Schips, Fina Climent, Julia Salmeron-Villalobos, Melika Bashiri, Silvia Ruiz-Gaspà, Dolors Costa, Sílvia Beà, Itziar Salaverria, Eva Giné, Leticia Quintanilla-Martinez, Pierre Brousset, Mark Raffeld, Elaine S Jaffe, Xose S Puente, Cristina López, Ferran Nadeu, Elias Campo
{"title":"Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma.","authors":"Ece Özoğul, Anna Montaner, Melina Pol, Gerard Frigola, Olga Balagué, Charlotte Syrykh, Pablo Bousquets-Muñoz, Romina Royo, Juliette Fontaine, Alexandra Traverse-Glehen, Marco M Bühler, Luca Giudici, Marco Roncador, Thorsten Zenz, Sylvain Carras, Severine Valmary-Degano, Laurence de Leval, Jan Bosch-Schips, Fina Climent, Julia Salmeron-Villalobos, Melika Bashiri, Silvia Ruiz-Gaspà, Dolors Costa, Sílvia Beà, Itziar Salaverria, Eva Giné, Leticia Quintanilla-Martinez, Pierre Brousset, Mark Raffeld, Elaine S Jaffe, Xose S Puente, Cristina López, Ferran Nadeu, Elias Campo","doi":"10.1038/s41408-024-01146-z","DOIUrl":"10.1038/s41408-024-01146-z","url":null,"abstract":"<p><p>Mantle cell lymphoma (MCL) is genetically characterized by the IG::CCND1 translocation mediated by an aberrant V(D)J rearrangement. CCND1 translocations and overexpression have been identified in occasional aggressive B-cell lymphomas with unusual features for MCL. The mechanism generating CCND1 rearrangements in these tumors and their genomic profile are not known. We have reconstructed the IG::CCND1 translocations and the genomic profile of 13 SOX11-negative aggressive B-cell lymphomas using whole genome/exome and target sequencing. The mechanism behind the translocation was an aberrant V(D)J rearrangement in three tumors and by an anomalous IGH class-switch recombination (CSR) or somatic hypermutation (SHM) mechanism in ten. The tumors with a V(D)J-mediated translocation were two blastoid MCL and one high-grade B-cell lymphoma. None of them had a mutational profile suggestive of DLBCL. The ten tumors with CSR/SHM-mediated IGH::CCND1 were mainly large B-cell lymphomas, with mutated genes commonly seen in DLBCL and BCL6 rearrangements in 6. Two cases, which transformed from marginal zone lymphomas, carried mutations in KLF2, TNFAIP3 and KMT2D. These findings expand the spectrum of tumors carrying CCND1 rearrangement that may occur as a secondary event in DLBCL mediated by aberrant CSR/SHM and associated with a mutational profile different from that of MCL.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":"166"},"PeriodicalIF":12.9,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach.","authors":"Jung Yoon,Taesung Jeon,Jung-Ah Kwon,Soo-Young Yoon","doi":"10.1038/s41408-024-01147-y","DOIUrl":"https://doi.org/10.1038/s41408-024-01147-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"19 1","pages":"165"},"PeriodicalIF":12.8,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
